Related Experiment Videos
Duloxetine Eli Lilly
1Department of Psychogeriatrics, Tampere University Hospital, Pitkaniemi, Finland. samia@koti.tpo.fi
Current Opinion in Investigational Drugs (London, England : 2000)
|September 5, 2002
Summary
Duloxetine, a serotonin and norepinephrine reuptake inhibitor, shows promise as a potent antidepressant. Clinical studies suggest it is well-tolerated, with anticipated launches for depression and incontinence.
Area of Science:
- Pharmacology
- Neuroscience
Background:
- Duloxetine is a serotonin (5-HT) and norepinephrine (NE) uptake inhibitor.
- In vivo studies indicate duloxetine's inhibition of 5-HT and NE transporters may induce antidepressant effects.
Purpose of the Study:
- To evaluate duloxetine's efficacy and tolerability as an antidepressant.
- To review clinical studies and market projections for duloxetine.
Main Methods:
- Meta-analysis of four clinical studies.
- Review of regulatory filings and financial analyst predictions.
Main Results:
- Duloxetine demonstrated potent antidepressant effects and good tolerability in clinical studies.
- Projected significant market revenue, with anticipated launches for depression and stress urinary incontinence.
Conclusions:
- Duloxetine is a well-tolerated and potent antidepressant.
- The drug is expected to achieve substantial market success for depression and incontinence treatment.